HOUSTON & MILAN--(BUSINESS WIRE)--Sibylla Biotech and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration agreement to discover and develop novel small-molecule cancer therapies known as Folding Interfering Degraders (FIDs), which disrupt the proper folding of target proteins and lead to their degradation.
Sibylla Biotech Enters a Drug Discovery Collaboration with Ono Pharmaceutical
Sibylla Biotech Appoints Sonia Poli as Chief Scientific Officer
Sibylla Biotech Appoints Dominique Bridon as Executive Chairman of the Board